Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25607314 | 0.90 | KLK7 (0.42) | MAOBMAOAPTGS1PTGS2LMNA | |
| SCHEMBL22967194 | 0.87 | MAOB (0.58) | MAOBMAOAPTGS1PTGS2GRM5 | |
| SCHEMBL1761237 | 0.83 | PTGS1 (0.64) | MAOBMAOAPTGS1PTGS2GRM5 | |
| SCHEMBL68886 | 0.77 | RAB9A (0.51) | MAOBMAOAGRM5HPGDHSD17B10 | |
| SCHEMBL13392164 | 0.76 | FABP6 (0.61) | PTGS1PTGS2LMNAKLK7CTRC | |
| SCHEMBL801234 | 0.75 | HDAC3 (0.55) | PTGS1PTGS2HDAC3HDAC4HDAC1 | |
| SCHEMBL9380831 | 0.75 | HPGD (0.43) | LMNAKLK7HPGDGFERHSD17B10 | |
| SCHEMBL2981516 | 0.74 | MAOB (0.74) | MAOBMAOAGRM5HPGDSMN1; SMN2 | |
| SCHEMBL16789730 | 0.74 | MAOB (0.50) | MAOBMAOAGRM5HPGDHTR1A | |
| SCHEMBL69670 | 0.74 | MAOB (0.50) | MAOBMAOAGRM5NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005095326-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1565443-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004024081-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-0843666-B1 | 4-SUBSTITUTED 5-POLYCYCLYLPYRIMIDINE HERBICIDES | DOW AGROSCIENCES LLC (US) | 2001-05-16 | — | — | EP | disclosed |
| US-5780465-A | 4-substituted 5-polycyclylpyrimidine herbicides | DOW AGROSCIENCES LLC (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0843666-A1 | 4-SUBSTITUTED 5-POLYCYCLYLPYRIMIDINE HERBICIDES | DOWELANCO (US) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997037978-A1 | 4-SUBSTITUTED 5-POLYCYCLYLPYRIMIDINE HERBICIDES | DOWELANCO (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAOB 802/4885MAOA 1118/4885PTGS1 1455/4885 |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | MAOB 399/4885MAOA 247/4885PTGS1 2315/4885 |
| US-20110251212-A1 | PIPERAZINE DERIVATIVES | GRIN2C, NR2C2, GRIN3A | MAOB 2242/4885MAOA 2664/4885PTGS1 2618/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | MAOB 1947/4885MAOA 2386/4885PTGS1 1725/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAOB 802/4885MAOA 1118/4885PTGS1 1455/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MAOB 802/4885MAOA 1118/4885PTGS1 1455/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | MAOB 407/4885MAOA 223/4885PTGS1 2366/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | MAOB 1516/4885MAOA 2100/4885PTGS1 3947/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | MAOB 1947/4885MAOA 2386/4885PTGS1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.